WebOct 19, 2024 · In the PROTECT-COVID-19 study, Michael Osthoff and his team from Basel University Hospital together with four other hospitals in Switzerland (Stadtspital Triemli and Kantonsspital St. Gallen) and abroad (Brazil and Mexico) investigated whether the use of the anti-inflammatory conestat alfa has a positive effect on the course of an infection ... WebIn the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a …
Forschungsgruppe Osthoff M. Departement Klinische …
WebFrom the aDivision of Internal Medicine, University Hospital Basel, Basel, Switzerland; bDepartment of Clinical Research and ... Switzerland; to Dr. Osthoff). Recombinant C1 esterase inhibitor was ... WebConestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 ... Michael Osthoff, PD Dr. med. Telephone: +41 61 328 6828 Email: [email protected] ... University Hospital Basel, Division of Internal Medicine [Recruiting] Basel, Switzerland, 4031 Contact: Contact: Michael Osthoff, PD Dr. med. … kicks high flyer waterfowl choke tubes
Recombinant human C1 esterase inhibitor (conestat alfa) in the ...
WebPublications. Osthoff. Michael. Prevention of Hepatitis B Reactivation in Patients Receiving Immunosuppressive Therapy: a Case Series and Appraisal of Society Guidelines. Etienne S; Vosbeck J; Bernsmeier C; Osthoff M. Journal of general internal medicine . 2024 . Antibiotic treatment duration in diverticulitis, complicated urinary tract ... WebRecombinant human C1 esterase inhibitor (conestat alfa) in the prevention of critical SARS-CoV-2 infection in hospitalized patients with COVID-19: a randomized, parallel-group, openlabel, multi-center exploratory trial. NFP 78 WebTrials (Jan 2024) . Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19) kicks high flyer optima choke max 5